Gastric/Stomach Cancer
Show Only Open Trials
1.
Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Resectable Cancer of the Esophagus or Gastroesophageal Junction (GEJ)
2.
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
- Study Status: Closed to Enrollment
- Sponsor: New York Cancer Consortium
- Disease Status and/or Stage: Gastric or Gastroesophageal Junction (GEJ) Cancer Not Amenable to Surgical Resection
3.
A random assignment phase II study of modified docetaxel, cisplatin, and fluorouracil (mDCF) versus parent DCF with growth factor support in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Metastatic or Unresectable Gastric or Gastroesophageal Junction (GEJ) Cancer
4.
A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer
- Study Status: Open to Enrollment
- Sponsor: Mayo Clinic, National Cancer Institute
- Disease Status and/or Stage: Locally Advanced, Recurrant or Metastatic disease
5.
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism (VTE) in Patients with Cancer
- Study Status: Closed to Enrollment
- Disease Status and/or Stage: Any Stage of Cancer
